TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs

American Journal of Pathology

Volumn 177, Issue 2, 2010, Pages 754-765

  Zhang, Yanmei ^a   Wang, Fuyuan ^a   Bhan, Urvashi ^a   Huffnagle, Gary B ^a   Toews, Galen B ^a   Standiford, Theodore J ^a   Olszewski, Michal A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD19 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; EFFECTOR CELL; FEMALE; FUNGAL STRAIN; GENE DELETION; GRANULOMA; HISTOPATHOLOGY; IMMUNE RESPONSE; KNOCKOUT MOUSE; LEUKOCYTE; LUNG CLEARANCE; LUNG INFECTION; LYMPHOCYTE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; POLARIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 77957285801     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091104     Document Type: Article

References (75)

1. Bottone EJ, Toma M, Johansson BE, Wormser GP: Capsule-deficient Cryptococcus neoformans in AIDS patients. Lancet 1985, 1:400
2. Nishikawa MM, Lazera MS, Barbosa GG, Trilles L, Balassiano BR, Macedo RC, Bezerra CC, Perez MA, Cardarelli P, Wanke B: Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: analysis of host and regional patterns. J Clin Microbiol 2003, 41:73-77
3. Perfect JR: Cryptococcus neoformans: a sugar-coated killer with designer genes. FEMS Immunol Med Microbiol 2005, 45:395-404
4. Attal HC, Grover S, Bansal MP, Chaubey BS, Joglekar VK: Capsule deficient Cryptococcus neoformans an unusual clinical presentation. J Assoc Physicians India 1983, 31:49-51
5. Bava J, Solari R, Isla G, Troncoso A: Atypical forms of Cryptococcus neoformans in CSF of an AIDS patient. J Infect Dev Ctries 2008, 2:403-405
6. Mackenzie DW, Hay RJ: Capsule-deficient Cryptococcus neoformans in AIDS patients. Lancet 1985, 1:642
7. Barluzzi R, Brozzetti A, Delfino D, Bistoni F, Blasi E: Role of the capsule in microglial cell-Cryptococcus neoformans interaction: impairment of antifungal activity but not of secretory functions. Med Mycol 1998, 36:189-197
8. Fromtling RA, Shadomy HJ, Jacobson ES: Decreased virulence in stable, acapsular mutants of Cryptococcus neoformans. Mycopathologia 1982, 79:23-29
9. Wilder JA, Olson GK, Chang YC, Kwon-Chung KJ, Lipscomb MF: Complementation of a capsule deficient Cryptococcus neoformans with CAP64 restores virulence in a murine lung infection. Am J Respir Cell Mol Biol 2002, 26:306-314
10. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE: The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994, 55:35-42
11. Arora S, Hernandez Y, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB: Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J Immunol 2005, 174:6346-6356
12. Lindell DM, Moore TA, McDonald RA, Toews GB, Huffnagle GB: Generation of antifungal effector CD8+ T cells in the absence of CD4+ T cells during Cryptococcus neoformans infection. J Immunol 2005, 174:7920-7928
13. Lindell DM, Moore TA, McDonald RA, Toews GB, Huffnagle GB: Distinct compartmentalization of CD4+ T-cell effector function versus proliferative capacity during pulmonary cryptococcosis. Am J Pathol 2006, 168:847-855
14. Buchanan KL, Murphy JW: Kinetics of cellular infiltration and cytokine production during the efferent phase of a delayed-type hypersensitivity reaction. Immunology 1997, 90:189-197
15. Buchanan KL, Fidel Jr PL, Murphy JW: Effects of Cryptococcus neoformans-specific suppressor T cells on the amplified anticryptococcal delayed-type hypersensitivity response. Infect Immun 1991, 59:29-35
16. Aguirre KM, Johnson LL: A role for B cells in resistance to Cryptococcus neoformans in mice. Infect Immun 1997, 65:525-530
17. Fung PY, Murphy JW: In vitro interactions of immune lymphocytes and Cryptococcus neoformans. Infect Immun 1982, 36:1128-1138
18. Vecchiarelli A: The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies. Curr Mol Med 2005, 5:413-420
19. Beenhouwer DO, Shapiro S, Feldmesser M, Casadevall A, Scharff MD: Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect Immun 2001, 69:6445-6455
20. Maitta RW, Datta K, Chang Q, Luo RX, Witover B, Subramaniam K, Pirofski LA: Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. Infect Immun 2004, 72:4810-4818
21. Torosantucci A, Chiani P, Bromuro C, De Bernardis F, Palma AS, Liu Y, Mignogna G, Maras B, Colone M, Stringaro A, Zamboni S, Feizi T, Cassone A: Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS One 2009, 4:e5392
22. Chen GH, McDonald RA, Wells JC, Huffnagle GB, Lukacs NW, Toews GB: The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect Immun 2005, 73:1788-1796
23. Chen GH, McNamara DA, Hernandez Y, Huffnagle GB, Toews GB, Olszewski MA: Inheritance of immune polarization patterns is linked to resistance versus susceptibility to Cryptococcus neoformans in a mouse model. Infect Immun 2008, 76:2379-2391
24. Decken K, Kohler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, Gately MK, Alber G: Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 1998, 66:4994-5000
25. Lovchik JA, Lyons CR, Lipscomb MF: A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol 1995, 13:116-124
26. Traynor TR, Kuziel WA, Toews GB, Huffnagle GB: CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J Immunol 2000, 164:2021-2027
27. Kawakami K, Hossain Qureshi M, Zhang T, Koguchi Y, Xie Q, Kurimoto M, Saito A: Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma- inducing cytokines. Cell Immunol 1999, 197:55-61
28. Olszewski MA, Huffnagle GB, McDonald RA, Lindell DM, Moore BB, Cook DN, Toews GB: The role of macrophage inflammatory protein-1alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection. J Immunol 2000, 165:6429-6436
29. Hernandez Y, Arora S, Erb-Downward JR, McDonald RA, Toews GB, Huffnagle GB: Distinct roles for IL-4 and IL-10 in regulating T2 immunity during allergic bronchopulmonary mycosis. J Immunol 2005, 174:1027-1036
30. Jain AV, Zhang Y, Fields WB, McNamara DA, Choe MY, Chen GH, Erb-Downward J, Osterholzer JJ, Toews GB, Huffnagle GB, Olszewski MA: Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Infect Immun 2009, 77:5389-5399
31. Hardison S, Ravi S, Wozniak K, Young M, Olszewski M, Wormley F: Pulmonary infection with an interferon-gamma producing cryptococcus neoformans strain results in classical macrophage activation and protection. Am J Pathol, 2010, 176:774-785
32. Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, Toews GB, Huffnagle GB, Olszewski MA: Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am J Pathol 2009, 175:2489-2500
33. Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N, Straubinger RK, Blessing M, McKenzie AN, Brombacher F, Alber G: IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 2007, 179:5367-5377
34. Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, Curtis JL, Huffnagle GB, Toews GB, Olszewski MA: Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am J Pathol 2009, 174:932-943
35. Muller U, Stenzel W, Kohler G, Polte T, Blessing M, Mann A, Piehler D, Brombacher F, Alber G: A gene-dosage effect for interleukin-4 receptor alpha-chain expression has an impact on Th2-mediated allergic inflammation during bronchopulmonary mycosis. J Infect Dis 2008, 198:1714-1721
36. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo M, Basaraba RJ, Konig T, Schleicher U, Koo MS, Kaplan G, Fitzgerald KA, Tuomanen EI, Orme IM, Kanneganti TD, Bogdan C, Wynn TA, Murray PJ: Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 2008, 9:1399-1406
37. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci 2008, 13:453-461
38. Babu S, Bhat SQ, Kumar NP, Anuradha R, Kumaran P, Gopi PG, Kolappan C, Kumaraswami V, Nutman TB: Attenuation of toll-like receptor expression and function in latent tuberculosis by coexistent filarial infection with restoration following antifilarial chemotherapy. PLoS Negl Trop Dis 2009, 3:e489
39. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE, Graeber TG, Sieling PA, Liu YJ, Rea TH, Bloom BR, Modlin RL: TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med 2005, 11:653-660
40. Mun HS, Aosai F, Norose K, Chen M, Piao LX, Takeuchi O, Akira S, Ishikura H, Yano A: TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection. Int Immunol 2003, 15:1081-1087
41. Abou Fakher FH, Rachinel N, Klimczak M, Louis J, Doyen N: TLR9-dependent activation of dendritic cells by DNA from Leishmania major favors Th1 cell development and the resolution of lesions. J Immunol 2009, 182:1386-1396
42. Yauch LE, Mansour MK, Levitz SM: Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo. Infect Immun 2005, 73:8429-8432
43. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM: Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001, 166:4620-4626
44. Biondo C, Midiri A, Messina L, Tomasello F, Garufi G, Catania MR, Bombaci M, Beninati C, Teti G, Mancuso G: MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur J Immunol 2005, 35:870-878
45. Nakamura K, Miyagi K, Koguchi Y, Kinjo Y, Uezu K, Kinjo T, Akamine M, Fujita J, Kawamura I, Mitsuyama M, Adachi Y, Ohno N, Takeda K, Akira S, Miyazato A, Kaku M, Kawakami K: Limited contribution of Toll-like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus neoformans. FEMS Immunol Med Microbiol 2006, 47:148-154
46. Wagner H: The immunobiology of the TLR9 subfamily. Trends in Immunology 2004, 25:381-386
47. Krieg AM: CpG motifs: the active ingredient in bacterial extracts? Nat Med 2003, 9:831-835
48. Bhan U, Trujillo G, Lyn-Kew K, Newstead MW, Zeng X, Hogaboam CM, Krieg AM, Standiford TJ: Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. Infect Immun 2008, 76:2895-2904
49. Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford TJ: TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J Immunol 2007, 179:3937-3946
50. Miyazato A, Nakamura K, Yamamoto N, Mora-Montes HM, Tanaka M, Abe Y, Tanno D, Inden K, Gang X, Ishii K, Takeda K, Akira S, Saijo S, Iwakura Y, Adachi Y, Ohno N, Mitsutake K, Gow NA, Kaku M, Kawakami K: Toll-like receptor 9-dependent activation of myeloid dendritic cells by deoxynucleic acids from Candida albicans. Infect Immun 2009, 77:3056-3064
51. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S: Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176:7335-7345
52. Nakamura K, Miyazato A, Xiao G, Hatta M, Inden K, Aoyagi T, Shiratori K, Takeda K, Akira S, Saijo S, Iwakura Y, Adachi Y, Ohno N, Suzuki K, Fujita J, Kaku M, Kawakami K: Deoxynucleic acids from Cryptococcus neoformans activate myeloid dendritic cells via a TLR9-dependent pathway. J Immunol 2008, 180:4067-4074
53. Dan JM, Wang JP, Lee CK, Levitz SM: Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS One 2008, 3:e2046
54. Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T: Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol 2005, 35:273-281
55. Olszewski MA, Huffnagle GB, Traynor TR, McDonald RA, Cook DN, Toews GB: Regulatory effects of macrophage inflammatory protein 1alpha/CCL3 on the development of immunity to Cryptococcus neoformans depend on expression of early inflammatory cytokines. Infect Immun 2001, 69:6256-6263
56. Huffnagle GB, Boyd MB, Street NE, Lipscomb MF: IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 1998, 160:2393-2400
57. Lipscomb MF, Huffnagle GB, Lovchik JA, Lyons CR, Pollard AM, Yates JL: The role of T lymphocytes in pulmonary microbial defense mechanisms. Arch Pathol Lab Med 1993, 117:1225-1232
58. Chiffoleau E, Heslan JM, Heslan M, Louvet C, Condamine T, Cuturi MC: TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell. Int Immunol 2007, 19:193-201
59. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF: TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007, 37:2205-2213
60. Padilla AM, Simpson LJ, Tarleton RL: Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol 2009, 183:1245-1252
61. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Sandor M, Lukacs NW, Chensue SW, Kunkel SL: TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. J Clin Invest 2009, 119:33-46
62. Herring AC, Falkowski NR, Chen GH, McDonald RA, Toews GB, Huffnagle GB: Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells. Infect Immun 2005, 73:39-49
63. Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S: Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol 2005, 61:10-17
64. Katakura T, Miyazaki M, Kobayashi M, Herndon DN, Suzuki F: CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 2004, 172:1407-1413
65. Stenzel W, Muller U, Kohler G, Heppner FL, Blessing M, McKenzie AN, Brombacher F, Alber G: IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol 2009, 174:486-496
66. Kawakami K, Koguchi Y, Qureshi MH, Yara S, Kinjo Y, Miyazato A, Nishizawa A, Nariuchi H, Saito A: Circulating soluble CD4 directly prevents host resistance and delayed-type hypersensitivity response to Cryptococcus neoformans in mice. Microbiol Immunol 2000, 44:1033-1041
67. Kobayashi M, Ito M, Sano K, Koyama M: Granulomatous and cytokine responses to pulmonary Cryptococcus neoformans in two strains of rats. Mycopathologia 2001, 151:121-130
68. Osterholzer JJ, Curtis JL, Polak T, Ames T, Chen GH, McDonald R, Huffnagle GB, Toews GB: CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans. J Immunol 2008, 181:610-620
69. Ito T, Schaller M, Hogaboam CM, Standiford TJ, Chensue SW, Kunkel SL: TLR9 activation is a key event for the maintenance of a mycobacterial antigen-elicited pulmonary granulomatous response. Eur J Immunol 2007, 37:2847-2855
70. Huffnagle GB, Yates JL, Lipscomb MF: T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun 1991, 59:1423-1433
71. Subramanian S, Mathai D: Clinical manifestations and management of cryptococcal infection. J Postgrad Med 2005, 51 Suppl 1:S21-S26
72. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ: Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 2009, 53:2804-2815
73. Saha DC, Goldman DL, Shao X, Casadevall A, Husain S, Limaye AP, Lyon M, Somani J, Pursell K, Pruett TL, Singh N: Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 2007, 14:1550-1554
74. Feldmesser M, Tucker S, Casadevall A: Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 2001, 9:273-278
75. Voelz K, Lammas DA, May RC: Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans. Infect Immun 2009, 77:3450-3457